SCHEMBL30438223

SCHEMBL30438223

CCC(=O)Oc1ncccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.47
LMNA P02545 2/20 0.45
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 1/20 0.42
ATM Q13315 1/20 0.42
NPC1 O15118 5/20 0.40
TSHR P16473 2/20 0.40
SSTR4 P31391 1/20 0.40
GLA P06280 1/20 0.40
POLB P06746 1/20 0.39
P2RY1 P47900 1/20 0.38
MAPK8 P45983 1/20 0.38
ELANE P08246 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ESR1 P03372 1/20 0.38
RECQL P46063 1/20 0.38
HIF1A Q16665 1/20 0.38
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27581563 0.87 L3MBTL1 (0.45) L3MBTL1LMNAKMT2AALDH1A1ATM
SCHEMBL4537895 0.86 L3MBTL1 (0.46) L3MBTL1LMNAKMT2AALDH1A1ATM
SCHEMBL27870422 0.83 L3MBTL1 (0.48) L3MBTL1LMNAKMT2AALDH1A1ATM
SCHEMBL4537897 0.82 L3MBTL1 (0.43) L3MBTL1LMNAKMT2AALDH1A1NPC1
SCHEMBL29094492 0.81 MAPT (0.41) L3MBTL1LMNAKMT2AALDH1A1NPC1
SCHEMBL1291161 0.81 L3MBTL1 (0.43) L3MBTL1LMNAKMT2AALDH1A1ATM
SCHEMBL18989973 0.80 ESR1 (0.39) L3MBTL1KMT2AALDH1A1NPC1TSHR
SCHEMBL28979476 0.80 ALDH1A1 (0.46) L3MBTL1LMNAKMT2AALDH1A1NPC1
SCHEMBL476475 0.80 LMNA (0.48) L3MBTL1LMNAKMT2AALDH1A1ATM
SCHEMBL29852510 0.79 SLC6A2 (0.44) L3MBTL1LMNANPC1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110177783-B Hormone receptor modulators for the treatment of metabolic conditions and disorders 阿德利克斯股份有限公司 2023-06-06 CN disclosed